“Public Health Consequences of Macrolide Use in Food Animals: A Deterministic Risk Assessment,” A Comment on:J. Food Prot. 67(5):980–992 (2004)

Abstract

macrolide use in food animals: a deterministic risk assessment. J. Food Prot. 67:980–992. 4. McDermott, P. F., S. M. Bodeis, and L. L. English. 2002. Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. J. Infect. Dis. 185:837–840. 5. U.S. Food and Drug Administration, Center for Veterinary Medicine. 2001. Risk assessment of the human health impact of fluoroquinolone resistant Campylobacter associated with the consumption of chicken. Available at: http://www.fda.gov/cvm/antimicrobial/Riskpasses.htm. Accessed 17 June 2004. 6. U.S. Food and Drug Administration, Center for Veterinary Medicine. 2003. Guidance for industry: evaluating the safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern. Document no. 152. Available at: http:// www.fda.gov/cvm/guidance/fguide152.pdf. Accessed 17 June 2004. 7. U.S. Food and Drug Administration, Center for Veterinary Medicine. 2004. Initial decision on proposed withdrawal of Baytril poultry NADA. Available at: http://www.fda.gov/cvm/antimicrobial/FQWithdrawal. html. Accessed 17 June 2004. 8. World Health Organization (WHO). 2003. Impacts of antimicrobial growth promoter termination in Denmark. The WHO international review panel’s evaluation of the termination of the use of antimicrobial growth promoters in Denmark. Ref. no. WHO/CDS/CPE/ZFK/ 2003.1. WHO, Geneva. 9. Zhao, C., B. Ge, J. De Villena, R. Sudler, E. Yeh, S. Zhao, D. G. White, D. Wagner, and J. Meng. 2001. Prevalence of Campylobacter spp., Escherichia coli, and Salmonella serovars in retail chicken, turkey, pork, and beef from the greater Washington, D.C., area. Appl. Environ. Microbiol. 67:5431–5436.